Rosetta Genomics Launches miRview(R) Lung Test

Over 90% Accuracy Identifying the Four Main Subtypes of Lung Cancer Using Small Tumor Quantities

Rosetta Genomics (NASDAQ:ROSG - News), a leading developer and provider of microRNA-based molecular diagnostic tests, announces that it has launched miRview® lung, the Company's advanced microRNA test that differentiates neuroendocrine tumors from non-small cell lung tumors (NSCLC), and then further subtypes neuroendocrine tumors into small cell lung cancer and carcinoid; and subtypes NSCLC tumors into squamous and non-squamous. miRview® lung will be marketed in the U.S. by Rosetta Genomics' oncology sales team and will be available internationally through the Company's various distribution partners.

Immucor Enters Into Definitive Agreement to be Acquired by TPG Capital

Immucor Shareholders to Receive $27.00 Per Share in Cash; Fully Diluted Equity Value of $1.973 Billion

Immucor, Inc. (Nasdaq:BLUD) (the "Company"), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital ("TPG") in a transaction with a fully diluted equity value of $1.973 billion.

OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass

Obstetrics & Gynecology study also considers OVA1's place in future surgical referral guidelines

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the OVA1 blood test were used in place of the currently recommended CA 125 blood test. The study builds on prior research that shows accurate assessment of an ovarian mass for cancer prior to surgery can affect both treatment decisions and health outcomes for women with ovarian cancer.

Genetic Technologies Secures US Approval for Launch of BREVAGen(TM) Breast Cancer Risk Test

- Genetic Technologies - first Australian CLIA approved laboratory - Runway clear for BREVAGen(TM) US launch, large addressable market with no direct competitors - GTG's Melbourne laboratory now one of only a few laboratories in the world with CLIA, NATA, ISO & RCPA accreditation/certification

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has gained certification of its Australian laboratory under the US Clinical Laboratories Improvements Amendments (CLIA) (42 U.S.C. section 263a) regulated by the Centers for Medicare and Medicaid (CMS). The certification was issued by the CMS central office which is responsible for approving non-US laboratories.